Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Sherief Abd-Elsalam

Status and phase: Unknown; Phase 3

Conditions: Bleeding Esophageal Varices

Treatments: Drug: Injection Sclerotherapy; Drug: N-butyl-2-cyanoacrylate

Study type: Interventional

Funder types: Other

Identifiers

NCT03388125

Active bleeding

Details and patient eligibility

About

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Full description

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Enrollment: 113 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• cirrhotic patients presented with actively bleeding

Exclusion criteria

• other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

113 participants in 2 patient groups

Injection Sclerotherapy

Active Comparator group

Description:

5% ethano lamine oleate

Treatment:

Drug: Injection Sclerotherapy

N-butyl-2-cyanoacrylate

Active Comparator group

Description:

N-butyl-2-cyanoacrylate injection group

Treatment:

Drug: N-butyl-2-cyanoacrylate